[
    [
        {
            "time": "2021-04-28",
            "original_text": "Eli Lilly Stock Crumbles As Covid Antibodies Hammer Sales, 2021 Outlook",
            "features": {
                "keywords": [
                    "Covid Antibodies",
                    "Sales",
                    "2021 Outlook"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly Stock Crumbles As Covid Antibodies Hammer Sales, 2021 Outlook",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-04-28",
            "original_text": "Eli Lilly and Company (LLY) Q1 2021 Earnings Call Transcript",
            "features": {
                "keywords": [
                    "Q1 2021",
                    "Earnings",
                    "Call Transcript"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Eli Lilly and Company (LLY) Q1 2021 Earnings Call Transcript",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-04-28",
            "original_text": "Eli Lil­ly Aban­dons IL-23 Psoriasis Program, Instead Will Focus On Ulcerative Colitis, Crohn's Disease Indications",
            "features": {
                "keywords": [
                    "IL-23",
                    "Psoriasis",
                    "Ulcerative Colitis",
                    "Crohn's Disease"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Eli Lil­ly Aban­dons IL-23 Psoriasis Program, Instead Will Focus On Ulcerative Colitis, Crohn's Disease Indications",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-04-28",
            "original_text": "Lilly’s COVID-19 antibody drugs are a top seller this quarter, but investors aren’t that excited",
            "features": {
                "keywords": [
                    "COVID-19",
                    "antibody drugs",
                    "top seller",
                    "investors"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Lilly’s COVID-19 antibody drugs are a top seller this quarter, but investors aren’t that excited",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-04-28",
            "original_text": "Eli Lilly profit forecast trimmed as vaccines dent U.S. demand for COVID-19 drugs",
            "features": {
                "keywords": [
                    "profit forecast",
                    "vaccines",
                    "U.S. demand",
                    "COVID-19 drugs"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly profit forecast trimmed as vaccines dent U.S. demand for COVID-19 drugs",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-04-28",
            "original_text": "Why Investors Didn't Like Lilly's Q1 Results",
            "features": {
                "keywords": [
                    "Investors",
                    "Lilly",
                    "Q1 Results"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Why Investors Didn't Like Lilly's Q1 Results",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-04-28",
            "original_text": "Eli Lilly (LLY) Q1 Earnings Miss, COVID-19 Drug Demand Low",
            "features": {
                "keywords": [
                    "Q1 Earnings",
                    "Miss",
                    "COVID-19 Drug Demand"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly (LLY) Q1 Earnings Miss, COVID-19 Drug Demand Low",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-04-28",
            "original_text": "Eli Lilly Shares Drop After Missing Q1 Earnings On Lower COVID-19 Drug Demand; 2021 Guidance Lagging Consensus",
            "features": {
                "keywords": [
                    "Shares Drop",
                    "Q1 Earnings",
                    "Lower COVID-19 Drug Demand",
                    "Guidance Lagging"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly Shares Drop After Missing Q1 Earnings On Lower COVID-19 Drug Demand; 2021 Guidance Lagging Consensus",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-04-28",
            "original_text": "Eli Lilly Cuts Earnings Forecast as Profits Fall Short",
            "features": {
                "keywords": [
                    "Earnings Forecast",
                    "Profits Fall Short"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly Cuts Earnings Forecast as Profits Fall Short",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-04-28",
            "original_text": "Eli Lilly profit misses as vaccines sap U.S. demand for COVID-19 drugs",
            "features": {
                "keywords": [
                    "profit misses",
                    "vaccines",
                    "U.S. demand",
                    "COVID-19 drugs"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly profit misses as vaccines sap U.S. demand for COVID-19 drugs",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-04-28",
            "original_text": "Eli Lilly shares slide 5% premarket as earnings fall short of estimates and guidance lags consensus",
            "features": {
                "keywords": [
                    "shares slide",
                    "earnings fall short",
                    "guidance lags"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly shares slide 5% premarket as earnings fall short of estimates and guidance lags consensus",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-04-28",
            "original_text": "Eli Lilly Misses Earnings Forecast, Lowers Full-Year Profit Guidance",
            "features": {
                "keywords": [
                    "Misses Earnings",
                    "Lowers Full-Year Profit"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly Misses Earnings Forecast, Lowers Full-Year Profit Guidance",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        }
    ]
]